CDXG: In the first half of 2025, revenue from controllable nuclear fusion-related products will account for less than 1% of the company's main business revenue
CDXG announced that the revenue from controllable nuclear fusion-related products will account for less than 1% of its main business revenue in the first half of 2025. The company's stock experienced an abnormal fluctuation, with the cumulative closing price deviation reaching 20% over three consecutive trading days from October 9 to October 13, 2025. After verification, the board of directors and major shareholders confirmed that there are no undisclosed significant matters. The electronic tubes independently developed by the company are used in controllable nuclear fusion RF power devices
According to the announcement from CDXG (600353.SH), the company's stock price deviation reached a cumulative increase of 20% over three consecutive trading days on October 9, October 10, and October 13, 2025. This constitutes an abnormal fluctuation in stock trading according to the relevant regulations of the Shanghai Stock Exchange Listing Rules.
Upon verification, as of the date of this announcement, the company's board of directors, controlling shareholders, actual controllers, and the company's second-largest shareholder confirmed that there are no significant matters related to the company that should have been disclosed but were not.
The company has noted the hot concept of "controlled nuclear fusion." The self-developed hundred-kilowatt and megawatt high-power electronic tubes are devices in the controlled nuclear fusion RF power supply system, used to achieve plasma heating of over one hundred million degrees. In the first half of 2025, the revenue from this product accounted for less than 1% of the company's main business revenue
